Short-Term Outcomes of ABO-Incompatible Living Donor Kidney Transplantation With Uniform Protocol: Significance of Baseline Anti-ABO Titer

• Published in: Transplantation proceedings 2016-04, Vol.48 (3), p.820-826
• Main Authors: Lee, K.W, Park, J.B, Oh, D.K, Na, B.G, Choi, J.Y, Cho, W.T, Lee, S.H, Park, H.J, Cho, D, Huh, W.S, Kim, S.J
• Format: Article
• Language: English
• Subjects: ABO Blood-Group System - immunology; Adult; Antibodies - blood; Blood Group Incompatibility; Female; Graft Rejection - blood; Humans; Immunoglobulins, Intravenous - therapeutic use; Immunologic Factors - therapeutic use; Kidney Transplantation; Living Donors; Male; Middle Aged; Retrospective Studies; Rituximab - therapeutic use; Surgery; Transplantation Conditioning
• ISSN: 0041-1345; 1873-2623
• DOI: 10.1016/j.transproceed.2016.01.027

Abstract Antibody-mediated rejection (AMR) is one of the major causes of poor outcomes in ABO-incompatible kidney transplantation (ABOi KT). Studies investigating AMR risk factors found that anti-ABO titer is a major issue. However, the significance of antibody titer has been debated. This retrospective study analyzed AMR risk factors in 59 patients who underwent ABOi KT between August 2010 and January 2015. We also analyzed AMR risk factors in recipients with high anti-ABO baseline titers (≥1:64 on dithiothreitol at 37°C phase or ≥1:256 on antihuman globulin phase). The 2-year patient survival rate was 95.8%, and the 2-year graft survival rate was 94.9%. Nine patients (15.3%) experienced clinical (6 of 59 [10.2%]) or subclinical (3 of 59 [5.1%]) AMR. One patient experienced graft loss from hyperacute rejection. AMR risk factor analysis revealed that baseline antibody titer was associated with incidence of AMR. In patients with high baseline titers, low doses of rituximab (200-mg single-dose), an antibody against CD20, was predictive for AMR. Six patients who received pretransplant intravenous immunoglobulin did not experience AMR even when they had high baseline antibody titers. Our results indicate that a high baseline antibody titer affected the incidence of AMR. ABOi KT candidates with high baseline titers need to undergo an intensified preconditioning protocol, including high-dose rituximab (375 mg/m2 ) and intravenous immunoglobulin.